PMC:7784824 / 8808-9179 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"169","span":{"begin":260,"end":263},"obj":"Gene"},{"id":"170","span":{"begin":119,"end":137},"obj":"Species"},{"id":"171","span":{"begin":155,"end":172},"obj":"Species"},{"id":"172","span":{"begin":288,"end":296},"obj":"Species"},{"id":"173","span":{"begin":314,"end":324},"obj":"Species"},{"id":"174","span":{"begin":333,"end":346},"obj":"Species"},{"id":"175","span":{"begin":139,"end":142},"obj":"Species"},{"id":"176","span":{"begin":174,"end":178},"obj":"Species"}],"attributes":[{"id":"A169","pred":"tao:has_database_id","subj":"169","obj":"Gene:4878"},{"id":"A170","pred":"tao:has_database_id","subj":"170","obj":"Tax:10376"},{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"Tax:5811"},{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"Tax:9606"},{"id":"A173","pred":"tao:has_database_id","subj":"173","obj":"Tax:2697049"},{"id":"A174","pred":"tao:has_database_id","subj":"174","obj":"Tax:11118"},{"id":"A175","pred":"tao:has_database_id","subj":"175","obj":"Tax:10376"},{"id":"A176","pred":"tao:has_database_id","subj":"176","obj":"Tax:5811"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Furthermore, 9 potential cross-reactive sera were included, i.e. IgM positivity against Cytomegalovirus (CMV) (n = 2), Epstein-Barr virus (EBV) (n = 2) or Toxoplasma gondii (Toxo) (n = 1); samples positive for rheumafactor (RF) (n = 1) or anti-nuclear factor (ANF) (n = 1)) and sera from patients positive for non-SARS-CoV-2 endemic coronaviruses (OC43 and NL63) (n = 2)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T90","span":{"begin":0,"end":371},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Furthermore, 9 potential cross-reactive sera were included, i.e. IgM positivity against Cytomegalovirus (CMV) (n = 2), Epstein-Barr virus (EBV) (n = 2) or Toxoplasma gondii (Toxo) (n = 1); samples positive for rheumafactor (RF) (n = 1) or anti-nuclear factor (ANF) (n = 1)) and sera from patients positive for non-SARS-CoV-2 endemic coronaviruses (OC43 and NL63) (n = 2)."}